Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Capital Expenditures (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Capital Expenditures data on record, last reported at -$5.0 million in Q4 2025.

  • For Q4 2025, Capital Expenditures changed N/A year-over-year to -$5.0 million; the TTM value through Dec 2025 reached -$3.0 million, changed N/A, while the annual FY2023 figure was $2.0 million, 33.33% down from the prior year.
  • Capital Expenditures reached -$5.0 million in Q4 2025 per RCUS's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $21.4 million in Q4 2021 and bottomed at -$5.1 million in Q3 2021.
  • Average Capital Expenditures over 5 years is $2.0 million, with a median of $1.5 million recorded in 2022.
  • The widest YoY moves for Capital Expenditures: up 6234.34% in 2021, down 458.27% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at $21.4 million in 2021, then plummeted by 90.65% to $2.0 million in 2022, then crashed by 300.0% to -$4.0 million in 2023, then skyrocketed by 125.0% to $1.0 million in 2024, then crashed by 600.0% to -$5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$5.0 million in Q4 2025, $1.0 million in Q1 2025, and $1.0 million in Q3 2024.